Immutep: Funding, Investors & Team (Sep 2026)
Immutep is a biopharmaceutical company that focuses on developing immunotherapeutics for cancer treatment. Their products include a T cell immunostimulatory factor for combining with chemotherapy and a therapeutic antibody for modifying immune responses in cancer. The company's technologies center around the LAG-3 immune control mechanism, which is crucial for regulating T cell immune responses.
Immutep has raised $61.2M across 2 funding rounds on record, the most recent an undisclosed round of $59.7M announced in Jun 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immutep Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Immutep Funding Rounds
Immutep raised $1.5M in a Grant announced in Sep 2022.
1.8 years later, an undisclosed round of $59.7M was announced in Jun 2024.
Immutep Founders and Leadership Team
Contact details for the Immutep team: 2 of 2 have an email address on file.
Start 14-day free trial →Immutep Funding Compared to Other Biotechnology Startups
Immutep's latest round of $59.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immutep in Biotechnology and Sydney
Companies Similar to Immutep
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Immutep Funding FAQs
What does Immutep do?
Immutep is a biopharmaceutical company that focuses on developing immunotherapeutics for cancer treatment. Their products include a T cell immunostimulatory factor for combining with chemotherapy and a therapeutic antibody for modifying immune responses in cancer. The company's technologies center around the LAG-3 immune control mechanism, which is crucial for regulating T cell immune responses.
How much funding has Immutep raised?
Immutep has raised $61.2M across 2 rounds on record. The most recent is an undisclosed round of $59.7M announced in Jun 2024.
When did Immutep last raise funding?
Immutep's most recent funding round on record is an undisclosed round of $59.7M, announced in Jun 2024.
Who founded Immutep?
FundedIQ lists John Hawken (Founder) at Immutep.
Who is the CEO of Immutep?
Marc Voigt is listed as CEO at Immutep.
Where is Immutep headquartered?
Immutep is based in Sydney, New South Wales, Australia.
How many employees does Immutep have?
Immutep is in the 11-50 employee band.
How does Immutep's funding compare to other Biotechnology startups?
Immutep's latest round of $59.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Immutep Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immutep is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.